Mr Kourosh Saeb-Parsy

University of Cambridge
Cambridge University Hospitals NHS Foundation Trust

University departments
Department of Surgery

Position: Reader
Personal home page:
Email:   Public email address:  ks10014@cam.ac.uk

PubMed journal articles - click here

Mr Kourosh Saeb-Parsy is pleased to consider applications from prospective PhD students.

Research description

Immunodeficient mice reconstituted with the human immune compartment (humanised mice), represent an invaluable model to study human cancer biology, as well as the safety and efficacy of cancer immunotherapies. In collaboration with colleagues at the Gurdon Institute, AstraZeneca and Medimmune, I lead a programme to investigate the safety and efficacy of human cancer immunotherapies using this experimental model. My focus is to use human tumour organoids transplanted in humanised mice as a more advanced and biologically-representative model to study human cancer biology and the safety and efficacy of cancer immunotherapies. A second focus of my research, in collaboration with colleagues at the Sanger Institute, is the burden of genetic mutation in normal human tissue and the associated insights into oncogenesis.

www.saeb-parsy.group.cam.ac.uk

Research Programme
Aerodigestive Cancer
Secondary Programme
Early Detection
Methods and technologies
In vivo modelling
Tumour type interests
Kidney
Liver
Pancreas
Keywords
Immuno-oncology
immunotherapy
safety
toxicity
tumoroids
PDX models
humanised mice

Key publications

1) Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, Cagan A, Murai K, Mahbubani K, Stratton MR, Fitzgerald RC, Handford PA, Campbell PJ, Saeb-Parsy K, Jones PH (2018). Somatic mutant clones colonize the human esophagus with age. Science 362(6417):911-917.
2) Broutier L, Mastrogiovanni G, Verstegen GMA, Francies HE, Morrill E, Bradshaw CR, Allen GE, Arnes R, Gaspersz MP, Georgakopoulos N, Koo B-K, Dietman S, Davies SE, Praseedom R, de Jonge J, IJzermans JNM, Wigmore SJ, Saeb-Parsy K, Garnett MJ, van der Laan LJW, Huch M. Tumour-derived Organoid Cultures model Primary Human Liver Cancer in vitro. Nature Medicine (2017) 23(12):1424-1435.
3) Rodrigues P, Patel SA, Harewood L, Olan I, Vojtasova E, Syafruddin SE, Zaini MN, Richardson EK, Burge J, Warren AY, Stewart GD, Saeb-Parsy K, Samarajiwa SA, Vanharanta S (2018) NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis. Cancer Discovery 8(7):850-865.
4) Sampaziotis F, Justin AW, Tysoe OC, Sawiak S, Godfrey EM, Upponi SS, Gieseck RL, de Brito MC, Berntsen NL, Gómez-Vázquez MJ, Ortmann D, Yiangou L, Ross A, Bargehr J, Bertero A, Zonneveld MCF, Pedersen MT, Pawlowski M, Valestrand L, Madrigal P, Georgakopoulos N, Pirmadjid N, Skeldon GM, Casey J, Shu W, Materek PM, Snijders KE, Brown SE, Rimland CA, Simonic I, Davies SE, Jensen KB, Zilbauer M, Gelson WTH, Alexander A, Sinha S, Hannan NRF, Wynn TA, Karlsen TH, MelumE, Markaki4 AE, Saeb-Parsy K*, Vallier L*. Reconstruction of the murine extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nature Medicine (2017) 23(8):954-963 (* equal contribution).
5) Sampaziotis F, Brito MC, Bertero A, Madrigal P, Saeb-Parsy K, Soares F, Schrumpf E, Melum E, Karlsen TH, Bradley JA, Gelson WTH, Davies S, Baker A, Kaser A, Alexander GJ, Hannan NRF, Vallier L (2015) Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nature Biotechnology 33: 845-52.
6) Chouchani ET, Pell VR, Gaude E, Aksentijevic´ D, Sundier SY, Robb EL, Logan A, Nadtochiy AM, Ord ENJ, Smith AC, Eyassu F, Shirley R, Hu C-H, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa ASH, Brookes PS, Davidson SM, Duchen MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg T, Murphy MP (2014) Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515(7527):431-5.